| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,145 | 0,160 | 21:56 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.07. | Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio and Its Combination with AI for the Diagnosis of Pancreatic Cysts | 397 | Business Wire | International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio AI Cellvizio increases accuracy... ► Artikel lesen | |
| 21.07. | Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth | 363 | Business Wire | H1 2026 sales reached €3,203K, up +44% at constant exchange rates (CER) and +39% as reported1 CellTolerance sales increased +145% to €0.9 million, driven by strong international expansion Strong... ► Artikel lesen | |
| 16.07. | Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity | 345 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 16.07. | Mauna Kea Technologies Secures €4 Million Optional Shareholder Loan To Support Commercial Expansion | 2 | pulse2.com | ||
| 15.07. | Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth | 594 | Business Wire | Shareholder loan agreement with long-term financial partner Vester Finance provides Mauna Kea with the contractual option to draw funds, with no obligation to do so, over the next 24 months Financing... ► Artikel lesen | |
| 06.07. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 274 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.06. | Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026 | 428 | Business Wire | All resolutions recommended by the Board of Directors were adopted, with the exception of the 15th
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio,... ► Artikel lesen | |
| 03.06. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 380 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.06. | Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying "Triple Healing", a Cellvizio- Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis | 316 | Business Wire | 100% of patients achieving Cellvizio-assessed triple healing remained relapse-free over 24 months (0 of 29), versus a ~33% relapse rate among those who did not A decade of converging, multi-center... ► Artikel lesen | |
| 20.05. | Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance Commercial Installation | 409 | Business Wire | IBS-related symptom prevalence in the region is among the highest in the world, reaching an average of 27% An ideal region uniquely positioned for CellTolerance's direct out-of-pocket commercial... ► Artikel lesen | |
| 18.05. | Mauna Kea Technologies Announces Nomination of 3 New Directors | 575 | Business Wire | Their recognized expertise will help accelerate the strategic transformation launched in 2025 Subject to approval at upcoming Annual General Meeting
Regulatory News:
Mauna Kea Technologies... ► Artikel lesen | |
| 04.05. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 338 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 30.04. | Mauna Kea Technologies: Publication of the 2025 Annual Financial Report | 765 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 28.04. | Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio To Be Presented at Digestive Disease Week 2026 | 739 | Business Wire | 10 Cellvizio-related abstracts, including landmark multicenter pancreatic cyst data, AI-driven IBD assessment, and new food intolerance applications, reinforce the breadth and depth of real-time... ► Artikel lesen | |
| 22.04. | Mauna Kea Technologies meldet starkes Wachstum im ersten Quartal 2026 | 1 | Investing.com Deutsch | ||
| 22.04. | Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025 | 827 | Business Wire | Fundamental balance sheet reset achieved through a 70% reduction in financial debt and €20M increase in equity Product sales momentum in 2025 driven by record U.S. sales performance (+38% CER)... ► Artikel lesen | |
| 15.04. | Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth | 437 | Business Wire | Q1 2026 sales reached €1,527K (excluding licensing), an increase of +68% at Constant Exchange Rate CER) and +57% as reported U.S. sales grew +34% CER (+21% reported) and +51% on an invoiced basis... ► Artikel lesen | |
| 08.04. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 350 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 17.03. | Mauna Kea Technologies Updates Its Financial Calendar | 1.649 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today... ► Artikel lesen | |
| 23.02. | Mauna Kea Technologies Accelerates International Expansion with New Regulatory Clearances in Switzerland and the United Kingdom | 1.347 | Business Wire | These clearances enable the commercialization of Cellvizio in two major markets and accelerate the Group's international expansion First order for the next-generation Cellvizio (Gen 3) platform... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,073 | +4,60 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| FAMICORD | 2,990 | +6,79 % | FamiCord plant Wechsel in das Scale-Segment der Frankfurter Börse | Der Vorstand der FamiCord AG, die früher als Vita 34 firmierte, will die Börsennotierung des Unternehmens vom regulierten Markt (Prime Standard) in das Freiverkehrssegment Scale der Frankfurter Wertpapierbörse... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,600 | +0,78 % | Dividendenbekanntmachungen (27.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ATHOS IMMOBILIEN AG AT0000616701 - 0,8 EUR FVCBANKCORP INC US36120Q1013 0,07 USD 0,0615 EUR GAS PLUS SPA IT0004098510 - 0,25 EUR GERATHERM... ► Artikel lesen | |
| CERENOME | 3,450 | 0,00 % | Plus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology Company | HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective... ► Artikel lesen | |
| MEDICLIN | 4,320 | -0,92 % | EQS-News: MEDICLIN AG: MEDICLIN beendet solides erstes Halbjahr 2026 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
MEDICLIN beendet solides erstes Halbjahr 2026
30.07.2026 / 12:37 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,040 | +0,99 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds | $4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants
SEATTLE, June 12, 2026 /PRNewswire/... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn Wound Irrigation Solution | BOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced it has received a new 510(k)... ► Artikel lesen | |
| VERU | 2,310 | -2,53 % | Veru Inc.: Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss | ||
| LIFEWARD | 7,340 | +0,14 % | Lifeward Ltd.: Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk Personal Exoskeleton | ||
| LIGHT AI | 0,110 | -3,08 % | Google Brings Green Light AI Traffic Pilot to Vancouver | ||
| IMUNON | 1,330 | -8,28 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen | |
| FRESENIUS | 46,650 | +5,16 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,310 | -0,36 % | Rallye bei Palantir: Rekordjagd geht weiter: DAX startet mit Gewinnen nach Zahlenreigen | © Foto: Arne Dedert/dpaEuropas Börsen haben am Dienstag weiter zugelegt. Starke Vorgaben und die Berichtssaison stützen die Rekordstimmung. Rallye bei Palantir, in Deutschland haben Bayer, Lufthansa... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 39,240 | +0,62 % | Ihre wichtigsten Termine: Spannende Zahlen von: Sony, Moderna, AbbVie, Eaton, ExxonMobil, Linde und Puma! | © Foto: picture alliance / CFOTO | CFOTOGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen |